Literature DB >> 23299823

Aspirin and clopidogrel for prevention of ischemic stroke.

Ruth M Thomson1, David C Anderson.   

Abstract

This review examines the role of platelets in ischemic stroke, platelet activation mechanisms, aspirin's rise as an antithrombotic agent, clopidogrel's appearance on the stage, a possible role for combination therapy, antiplatelet resistance, practical considerations, and future directions. Reviewed in this chapter are issues central to optimal antiplatelet therapy: efficacy, safety, resistance, and biochemical/laboratory testing. Current guidelines do not recommend combination aspirin and clopidogrel use, however recent research indicates dual antiplatelet therapy with combined aspirin and clopidogrel may have specific roles in secondary prevention of ischemic stroke. A cautious and analytical interpretation of the literature is advised before application of this knowledge to clinical practice. The best recommendation at this time is to follow the published guidelines for secondary prevention of ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23299823     DOI: 10.1007/s11910-012-0327-y

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  73 in total

1.  Hemorrhagic complications associated with aspirin: an underestimated hazard in clinical practice?

Authors:  Jolanta M Siller-Matula
Journal:  JAMA       Date:  2012-06-06       Impact factor: 56.272

2.  Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin.

Authors:  Jolanta M Siller-Matula; Georg Delle-Karth; Günter Christ; Thomas Neunteufl; Gerald Maurer; Kurt Huber; Alexander Tolios; Christa Drucker; Bernd Jilma
Journal:  Int J Cardiol       Date:  2012-02-02       Impact factor: 4.164

3.  Impaired platelet-connective-tissue reaction in man after aspirin ingestion.

Authors:  H J Weiss; L M Aledort
Journal:  Lancet       Date:  1967-09-02       Impact factor: 79.321

4.  Adenosine diphosphate-induced platelet aggregation and myocardial infarction in swine.

Authors:  L Jorgensen; H C Rowsell; T Hovig; M F Glynn; J F Mustard
Journal:  Lab Invest       Date:  1967-12       Impact factor: 5.662

5.  Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin.

Authors:  Keiichiro Yamane; Tomoyuki Ikeda; Ryoji Taniguchi; Shin Watanabe; Mitsunori Kawato; Hirokazu Kondo; Ryutaro Shirakawa; Tomohito Higashi; Masanao Toma; Arata Tabuchi; Toshihiro Tamura; Kanako Takahashi; Haruyo Watanabe; Yuka Yoshikawa; Toru Kita; Takeshi Kimura; Hisanori Horiuchi
Journal:  J Atheroscler Thromb       Date:  2012-08-09       Impact factor: 4.928

6.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

7.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.

Authors:  A Schömig; F J Neumann; A Kastrati; H Schühlen; R Blasini; M Hadamitzky; H Walter; E M Zitzmann-Roth; G Richardt; E Alt; C Schmitt; K Ulm
Journal:  N Engl J Med       Date:  1996-04-25       Impact factor: 91.245

8.  Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.

Authors:  G A FitzGerald; J A Oates; J Hawiger; R L Maas; L J Roberts; J A Lawson; A R Brash
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

9.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321

10.  Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.

Authors:  Takao Tamura; Toshiyuki Sakaeda; Kaori Kadoyama; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2012-07-25       Impact factor: 3.738

View more
  5 in total

1.  A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel.

Authors:  Katsuyuki Tozawa; Tadayuki Oshima; Takuya Okugawa; Tomohiro Ogawa; Yoshio Ohda; Toshihiko Tomita; Nobuyuki Hida; Hirokazu Fukui; Kazutoshi Hori; Jiro Watari; Shiro Nakamura; Hiroto Miwa
Journal:  Dig Dis Sci       Date:  2014-08       Impact factor: 3.199

Review 2.  Translational strategies for neuroprotection in ischemic stroke--focusing on acid-sensing ion channel 1a.

Authors:  Zaven O'Bryant; Kiara T Vann; Zhi-Gang Xiong
Journal:  Transl Stroke Res       Date:  2014-01-05       Impact factor: 6.829

Review 3.  Na(+)/H(+) exchanger in the regulation of platelet activation and paradoxical effects of cariporide.

Authors:  He Benny Chang; Xin Gao; Rachel Nepomuceno; Shaoshan Hu; Dandan Sun
Journal:  Exp Neurol       Date:  2015-01-13       Impact factor: 5.330

4.  Simultaneous Analysis of Clopidogrel Bisulfate, Acetylsalicylic Acid and Atorvastatin calcium in Tablets by HPLC Method.

Authors:  A M Spiridon; J Neamtu; I Belu; T S Turcu-Stiolica; O Croitoru
Journal:  Curr Health Sci J       Date:  2015-04-10

5.  Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.

Authors:  Roberta Galeazzi; Fabiola Olivieri; Liana Spazzafumo; Giuseppina Rose; Alberto Montesanto; Simona Giovagnetti; Sara Cecchini; Gelsomina Malatesta; Raffaele Di Pillo; Roberto Antonicelli
Journal:  Drugs Aging       Date:  2018-07       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.